中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
6期
501-502,503
,共3页
乌司他丁%慢性阻塞性肺疾病%临床疗效
烏司他丁%慢性阻塞性肺疾病%臨床療效
오사타정%만성조새성폐질병%림상료효
Ulinastatin%Chronic obstructive pulmonary disease%Clinical efficacy
目的：探讨乌司他丁对慢性阻塞性肺疾病（COPD）急性加重期有创机械通气患者的肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）的调节作用及治疗效果的影响。方法：选取2012年1月至2013年12月某院重症医学科收治的COPD急性加重期有创机械通气患者120例，按随机数字表法随机分为治疗组与对照组（各60例），对照组给予常规治疗，治疗组在常规治疗基础上加用乌司他丁。采用酶联免疫吸附试验（ELISA）法测定两组患者血浆中的TNF-α、IL-6浓度，观察两组患者血清中炎性因子的浓度变化、住院时间、机械通气治疗时间、并发症发生例数及治疗费用。结果：所有患者治疗后均脱呼吸机好转出院。两组患者经治疗后血清TNF-α、IL-6浓度均明显降低，但治疗组降低更明显，两组差异有统计学意义（P＜0.05）；治疗组患者住院时间、机械通气治疗时间、并发症发生例数及治疗费用均低于对照组患者（P＜0.05）。结论：乌司他丁能减轻COPD有创机械通气患者的机体炎症反应，缩短治疗时间，改善短期预后，有较好的临床疗效及经济效应。
目的：探討烏司他丁對慢性阻塞性肺疾病（COPD）急性加重期有創機械通氣患者的腫瘤壞死因子α（TNF-α）、白細胞介素6（IL-6）的調節作用及治療效果的影響。方法：選取2012年1月至2013年12月某院重癥醫學科收治的COPD急性加重期有創機械通氣患者120例，按隨機數字錶法隨機分為治療組與對照組（各60例），對照組給予常規治療，治療組在常規治療基礎上加用烏司他丁。採用酶聯免疫吸附試驗（ELISA）法測定兩組患者血漿中的TNF-α、IL-6濃度，觀察兩組患者血清中炎性因子的濃度變化、住院時間、機械通氣治療時間、併髮癥髮生例數及治療費用。結果：所有患者治療後均脫呼吸機好轉齣院。兩組患者經治療後血清TNF-α、IL-6濃度均明顯降低，但治療組降低更明顯，兩組差異有統計學意義（P＜0.05）；治療組患者住院時間、機械通氣治療時間、併髮癥髮生例數及治療費用均低于對照組患者（P＜0.05）。結論：烏司他丁能減輕COPD有創機械通氣患者的機體炎癥反應，縮短治療時間，改善短期預後，有較好的臨床療效及經濟效應。
목적：탐토오사타정대만성조새성폐질병（COPD）급성가중기유창궤계통기환자적종류배사인자α（TNF-α）、백세포개소6（IL-6）적조절작용급치료효과적영향。방법：선취2012년1월지2013년12월모원중증의학과수치적COPD급성가중기유창궤계통기환자120례，안수궤수자표법수궤분위치료조여대조조（각60례），대조조급여상규치료，치료조재상규치료기출상가용오사타정。채용매련면역흡부시험（ELISA）법측정량조환자혈장중적TNF-α、IL-6농도，관찰량조환자혈청중염성인자적농도변화、주원시간、궤계통기치료시간、병발증발생례수급치료비용。결과：소유환자치료후균탈호흡궤호전출원。량조환자경치료후혈청TNF-α、IL-6농도균명현강저，단치료조강저경명현，량조차이유통계학의의（P＜0.05）；치료조환자주원시간、궤계통기치료시간、병발증발생례수급치료비용균저우대조조환자（P＜0.05）。결론：오사타정능감경COPD유창궤계통기환자적궤체염증반응，축단치료시간，개선단기예후，유교호적림상료효급경제효응。
OBJECTIVE:To investigate the regulatory effects of ulinastatin on tumor necrosis factor-α(TNF-α)and interleukin 6(IL-6)and its clinical efficacy in patients with acute exacerbation of chronic obstructive pulmonary disease(COPD)undergoing invasive mechanical ventilation. METHODS:A total of 64 patients with acute exacerbation of COPD admitted to our hospital from Jan. 2012 to Dec. 2013 were randomly assigned to receive either routine therapy alone(control group)or routine therapy plus Ulina-statin (trial group) of 60 each. Plasma levels of TNF-α and IL-6 were determined by ELISA and the inflammatory factors in both groups,length of hospital stay,mechanical ventilation time,the number of complications and treatment costs were recorded. RE-SULTS:All patients weaned successfully from the mechanical ventilator and discharged from hospital with recovery after treatment. Serum levels of TNF-α and IL-6 in both groups declined significantly after treatment,much as in the treatment group,showing sta-tistically significant differences between two groups (P<0.05);the length of hospital stay,the mechanical ventilation time,the number of complications and the treatment costs were all lower in the trial group than in the control group (P<0.05). CONCLU-SIONS:Ulinastatin can relieve ventilation it is of good clinical efficacy and economic efficacy inflammatory response,shorten treat-ment time,improve short-term outcome in patients with COPD receiving invasive mechanical ventilation. It is of good clinical and economic efficacy.
